What is Ciloa?
Ciloa is a biotechnology firm specializing in the development of advanced therapies, built upon over 15 years of research in exosome-based drug development technology. The company's proprietary platform enables the production of all types of membrane proteins in their native conformation on exosomes, as well as the loading of cytosolic proteins. This capability is crucial for targeting notoriously difficult 'undruggable' protein targets, which are often key to treating complex diseases. Ciloa's technology has broad applications across oncology, infectiology, cardiology, genetic disorders, and neurological conditions, leveraging the natural properties of exosomes such as their immuno-stimulatory effects, biocompatibility, and ability to cross the blood-brain barrier.
How much funding has Ciloa raised?
Ciloa has raised a total of $13M across 2 funding rounds:
Other Financing Round
$5.4M
Other Financing Round
$7.6M
Other Financing Round (2022): $5.4M with participation from Bpifrance
Other Financing Round (2025): $7.6M led by Agence nationale de la recherche ANR
Key Investors in Ciloa
Agence nationale de la recherche ANR
The Agence nationale de la recherche (ANR) is the French national agency dedicated to funding project-based research across diverse scientific fields, supporting innovation and international collaboration, particularly in sustainable development.
Bpifrance
Bpifrance is a French public investment bank that finances companies at all stages of their development, supporting innovation, international expansion, and export activities through credit, guarantees, and equity.
What's next for Ciloa?
With substantial enterprise-level funding and a recent strategic investment, Ciloa is poised for significant expansion and market penetration. The company's focus on overcoming 'undruggable' targets positions it at the forefront of therapeutic innovation. Future endeavors will likely involve scaling production capabilities, advancing clinical trials for its most promising exosome-based therapies, and forging strategic partnerships to accelerate the delivery of these novel treatments to patients across a spectrum of critical diseases. This capital infusion will be instrumental in navigating the complex regulatory pathways and solidifying Ciloa's position as a leader in exosome therapeutics.
See full Ciloa company page
